Abstract
Pediatric patients are at risk for adverse drug reactions, and oncologic patients are at an even higher risk. (1) This study aims to describe and quantify the long-term dermatologic sequelae and drug reactions in patients who received allogeneic hematopoietic stem cell transplantation (allo-HSCT) as children. 273 patients who received allo-HSCT as children from the period 01/27/2002- 01/27/2022 at Duke University Hospital were identified. All patient visits from the period of 01/1996-01/2020 were obtained via the Duke Enterprise Data Unified Content Explorer (DEDUCE).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
